Medistep Health.

Why is Medistep Healthcare Ltd falling/rising?

As of 18-Jul, Medistep Healthcare Ltd's stock price is at 19.35, reflecting a 5.74% increase today and a 4.59% gain over the past week. However, it has declined 10.00% over the past month and 16.23% year-to-date, with decreasing investor participation suggesting potential long-term challenges.

As of 18-Jul, Medistep Healthcare Ltd's stock price is rising, currently at 19.35, reflecting a change of 1.05 or 5.74% increase. This upward movement is notable as it has outperformed its sector by 7.15% today. Additionally, the stock has shown a positive performance over the past week, with a gain of 4.59%, while the benchmark Sensex has only increased by 0.53% in the same period.<BR><BR>However, it is important to note that despite today's rise, the stock has experienced a decline of 10.00% over the past month and a year-to-date drop of 16.23%. The current price is higher than the 5-day moving averages, indicating a short-term positive trend, but it remains lower than the longer-term moving averages (20-day, 50-day, 100-day, and 200-day), suggesting that the stock may still be under pressure in the longer term.<BR><BR>Investor participation appears to be declining, with a delivery volume of 6,000 shares on 16 July, which is down by 9.09% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, as it constitutes 2% of the 5-day average traded value. Overall, while the stock is currently rising, its longer-term performance and declining investor participation may indicate underlying challenges.

Which are the latest news on Medistep Health.?

What does Medistep Health. do?

Medistep Healthcare Ltd, a micro-cap company incorporated in June 2023, operates in the diversified consumer products industry and recently acquired M/s MG Pharma. As of June 2024, it reported net sales of 11 Cr and a net profit of 1 Cr, with a market cap of INR 28 Cr.

Overview:<BR>Medistep Healthcare Ltd operates in the diversified consumer products industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on June 05, 2023, as a Public Limited Company. It subsequently acquired the business of M/s MG Pharma from one of its promoters, Ms. Prajapati Hetalben Girdharilal, through a business transfer agreement dated July 02, 2023. The latest quarterly results reported net sales and net profit for June 2024.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 11 Cr (Quarterly Results - Jun 2024)<BR>- Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2024)<BR>- Market-cap value: INR 28 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 5.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.12<BR>- Return on Equity: 15.81%<BR>- Price to Book: 0.73<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

How big is Medistep Health.?

As of 10th June, Medistep Healthcare Ltd has a market capitalization of 28.00 Cr, with recent net sales of 11.25 Cr and a net profit of 1.02 Cr for June 2024. Shareholder's funds are 16.83 Cr, and total assets amount to 22.98 Cr as of March 2025.

As of 10th June, Medistep Healthcare Ltd has a market capitalization of 28.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarterly performance for June 2024, Medistep Healthcare Ltd reported Net Sales of 11.25 Cr and a Net Profit of 1.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds stand at 16.83 Cr and Total Assets amount to 22.98 Cr.

Who are the peers of the Medistep Health.?

Medistep Health's peers include A B M Internatl., Aro Granite Inds, Madhav Marbles, Pearl Polymers, Lexus Granito, SPP Polymer, Ahimsa Industrie, SMVD Poly Pack, and Amin Tannery. Medistep Health shows excellent management and growth, while its peers generally exhibit below-average performance in these areas.

Peers: The peers of Medistep Health are A B M Internatl., Aro Granite Inds, Madhav Marbles, Pearl Polymers, Lexus Granito, SPP Polymer, Ahimsa Industrie, SMVD Poly Pack, Amin Tannery.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medistep Health., while Below Average management risk is found at A B M Internatl., Aro Granite Inds, Madhav Marbles, Pearl Polymers, Lexus Granito, SPP Polymer, Ahimsa Industrie, SMVD Poly Pack, and Amin Tannery. Excellent growth is seen at Medistep Health., while Below Average growth is noted at A B M Internatl., Aro Granite Inds, Madhav Marbles, Pearl Polymers, Lexus Granito, SPP Polymer, Ahimsa Industrie, SMVD Poly Pack, and Amin Tannery. Medistep Health. has a Good capital structure, while Below Average capital structure is present at A B M Internatl., Aro Granite Inds, Madhav Marbles, Pearl Polymers, Lexus Granito, SPP Polymer, Ahimsa Industrie, SMVD Poly Pack, and Amin Tannery.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ahimsa Industrie at 11.76%, while the peer with the lowest 1-year return is Lexus Granito at -57.73%. Medistep Health.'s 1-year return is not available for comparison. Additionally, several peers, including Aro Granite Inds, Pearl Polymers, Lexus Granito, SPP Polymer, and Amin Tannery, have negative six-month returns.

Is Medistep Health. overvalued or undervalued?

As of November 13, 2025, Medistep Health is considered very attractive with a PE ratio of 9.37 and an EV to EBIT ratio of 6.86, significantly lower than its peers, indicating it is undervalued despite a strong recent weekly return of 21.88%.

As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. <BR><BR>In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen.

How has been the historical performance of Medistep Health.?

Medistep Health has shown significant growth over the past three years, with net sales increasing from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 4.14 Cr. The company has also improved its equity capital and cash flow management during this period.

Answer:<BR>The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 22.98 Cr. Cash flow from financing activities showed a net inflow of 1.00 Cr in Mar'25, compared to an outflow of 7.00 Cr in Mar'24, indicating improved cash management. Overall, Medistep Health has demonstrated robust growth in sales and profitability, alongside an increase in equity and total assets.